Testování přidání protirakovinného léku, BAY 1895344, k obvyklé chemoterapii s FOLFIRI u pokročilého nebo metastatického karcinomu žaludku a střev
Fáze I/Ib studie s ATR inhibitorem BAY 1895344 v kombinaci s FOLFIRI u GI malignit se zaměřením na metastatické kolorektální a žaludeční/gastroezofageální karcinomy
This phase I trial investigates the best dose, possible benefits and/or side effects of BAY 1895344 in combination with FOLFIRI in treating patients with stomach or intestinal cancer that that may have spread from where it first started to nearby tissue, lymph nodes, or distant parts of the body (advanced) or has spread from where it first started (primary site) to other places in the body (metastatic). BAY 1895344 may stop the growth of tumor cells by blocking some of the enzymes needed for cell growth. Chemotherapy drugs, such as irinotecan, fluorouracil, and leucovorin, (called FOLFIRI in short) work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Giving BAY 1895344 in combination with FOLFIRI may help shrink advanced or metastatic stomach and/or intestinal cancer.
Přehled studie
Postavení
Postavení
Podmínky
Podmínky
- Klinické stadium III rakoviny žaludku AJCC v8
- Adenokarcinom gastroezofageální junkce AJCC v8
- Klinické stadium IV rakoviny žaludku AJCC v8
- Adenokarcinom gastroezofageální junkce AJCC v8
- Metastatický adenokarcinom gastroezofageální junkce
- Metastatický kolorektální karcinom
- Stádium IV Kolorektální karcinom AJCC v8
- Stádium III Kolorektální karcinom AJCC v8
- Pokročilý karcinom žaludku
- Metastatický karcinom trávicího systému
- Metastatický karcinom žaludku
- Pokročilý adenokarcinom gastroezofageální junkce
- Pokročilý kolorektální karcinom
- Pokročilý karcinom trávicího systému
Intervence / Léčba
Intervence / Léčba
Detailní popis
PRIMARY OBJECTIVE:
I. Determine the safety and maximum tolerated dose (MTD) of elimusertib (BAY 1895344) with leucovorin calcium, fluorouracil, and irinotecan hydrochloride (FOLFIRI).
SECONDARY OBJECTIVES:
I. To observe and record anti-tumor activity by overall response rate (ORR), progression-free survival (PFS), and overall survival (OS).
II. Determine the response and clinical benefit rate (complete response + partial response + stable disease) of BAY 1895344 with FOLFIRI in colorectal and gastric/gastroesophageal cancers.
III. Evaluate tumor and peripheral blood mononuclear cell (PBMC) deoxyribonucleic acid (DNA) damage signaling in the context of the chemotherapy backbone alone and when combined with BAY 1895344.
IV. Evaluate the pharmacokinetics (PK) profile of fluorouracil (5-FU) and irinotecan.
V. Evaluate the PK profile of BAY 1895344. VI. Evaluate the relationship between ATM status by immunohistochemistry (IHC) and clinical efficacy of the BAY 1895344/FOLFIRI combination.
EXPLORATORY OBJECTIVES:
I. Evaluate the exposure-response relationship between drug exposures and toxicity and response, and UGT1A1 genotype.
II. Evaluate the relationship between tumor mutations and clinical efficacy of the BAY 1895344/FOLFIRI combination.
OUTLINE: This is a dose-escalation study of elimusertib, irinotecan, and fluorouracil with fixed-dose leucovorin followed by a dose-expansion study.
Patients receive elimusertib orally (PO) once daily (QD) on days 2, 3, 16, and 17 and irinotecan hydrochloride intravenously (IV) over 90 minutes, fluorouracil IV over 46 hours, and leucovorin calcium IV on days 1 and 15. Cycles repeat every 28 day in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy during screening and on study and blood sample collection and imaging throughout the study.
After completion of study treatment, patients are followed up for 30 days and then every 3 months for up to 1 year or until their disease gets worse or they begin a new treatment for their cancer.
Typ studie
Typ studie
Zápis (Aktuální)
Zápis
Fáze
Fáze
- Fáze 1
Kontakty a umístění
Studijní místa
-
-
California
-
Duarte, California, Spojené státy, 91010
- City of Hope Comprehensive Cancer Center
-
-
Maryland
-
Bethesda, Maryland, Spojené státy, 20892
- National Institutes of Health Clinical Center
-
Bethesda, Maryland, Spojené státy, 20892
- National Cancer Institute Developmental Therapeutics Clinic
-
-
Missouri
-
City of Saint Peters, Missouri, Spojené státy, 63376
- Siteman Cancer Center at Saint Peters Hospital
-
Creve Coeur, Missouri, Spojené státy, 63141
- Siteman Cancer Center at West County Hospital
-
St Louis, Missouri, Spojené státy, 63110
- Washington University School of Medicine
-
St Louis, Missouri, Spojené státy, 63129
- Siteman Cancer Center-South County
-
St Louis, Missouri, Spojené státy, 63136
- Siteman Cancer Center at Christian Hospital
-
-
New York
-
New York, New York, Spojené státy, 10032
- NYP/Columbia University Medical Center/Herbert Irving Comprehensive Cancer Center
-
-
Pennsylvania
-
Pittsburgh, Pennsylvania, Spojené státy, 15232
- UPMC Hillman Cancer Center
-
-
Kritéria účasti
Kritéria způsobilosti
Kritéria způsobilosti
Věk způsobilý ke studiu
Přijímá zdravé dobrovolníky
Pohlaví způsobilá ke studiu
Popis
Inclusion Criteria:
-
For Dose Escalation: Patients must have histologically or cytologically confirmed advanced or metastatic gastrointestinal (GI) cancers with Response Evaluation Criteria in Solid Tumors 1.1 (RECIST1.1) measurable disease who have progressed on at least one prior treatment for metastatic disease and for whom FOLFIRI is considered a reasonable treatment option. Patients with mismatch repair deficiency should have progressed on immunotherapy
-
For Dose Expansion: Patients must have either:
- Colorectal cancer who have previously progressed on irinotecan and tolerated an irinotecan dose equal to or greater than the recommended phase 2 dose (RP2D). If they have mismatch repair deficiency they should have progressed on immunotherapy OR
- Gastroesophageal cancer who have progressed on at least one first-line therapy for metastatic disease. If they have mismatch repair deficiency they should have progressed on immunotherapy
-
For Dose Expansion: Patients be willing to undergo biopsies for research purposes only. The accessible tumor can be the primary or metastatic tumor site. Both research biopsies should be taken from the same tumor site
-
Patients must have progressive disease on at least first-line therapy for metastatic disease. Previous treatment with irinotecan is allowed
-
Age >= 18 years. Because no dosing or adverse event data are currently available on the use of BAY 1895344 in combination with FOLFIRI in patients <18 years of age, children are excluded from this study
-
Eastern Cooperative Oncology Group (ECOG) performance status =< 1
-
Leukocytes >= 3,000/mcL
-
Absolute neutrophil count >= 1,500/mcL
-
Platelets >= 100,000/mcL
-
Total bilirubin =< 1.5 x institutional upper limit of normal (ULN)
-
Aspartate aminotransferase (AST) (serum glutamic-oxaloacetic transaminase [SGOT])/alanine aminotransferase (ALT) (serum glutamate pyruvate transaminase [SGPT]) =< 3 x institutional ULN
-
Glomerular filtration rate (GFR) >= 60 mL/min/1.73 m^2 using the Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation
-
International normalization ratio (INR) =< 1.5 × ULN unless participant is receiving anticoagulant therapy, in which case prothrombin time (PT) or activated partial thromboplastin time (aPTT) should be within expected therapeutic range of anticoagulants. If patient has a new diagnosis of venous thromboembolism (VTE), then patient should be appropriately anticoagulated with low molecular weight heparin (LMWH) or direct acting oral anticoagulants (DOACs) and be clinically stable for at least 1 week post treatment onset
-
Human immunodeficiency virus (HIV)-infected patients on effective anti-retroviral therapy, that does not interact with study therapy, with undetectable viral load within 6 months are eligible for this trial
-
For patients with evidence of chronic hepatitis B virus (HBV) infection, the HBV viral load must be undetectable on suppressive therapy that does not interact with study therapy, if indicated
-
Patients with a history of hepatitis C virus (HCV) infection must have been treated and cured. For patients with HCV infection who are currently on treatment, they are eligible if they have an undetectable HCV viral load and HCV therapy does not interact with study therapy
-
Patients with treated brain metastases are eligible if follow-up brain imaging after central nervous system (CNS)-directed therapy shows no evidence of progression
-
Patients with a prior or concurrent malignancy whose natural history or treatment does not have the potential to interfere with the safety or efficacy assessment of the investigational regimen are eligible for this trial
-
Patients with known history or current symptoms of cardiac disease, or history of treatment with cardiotoxic agents, should have a clinical risk assessment of cardiac function using the New York Heart Association Functional Classification. To be eligible for this trial, patients should be class 2B or better
-
The effects of BAY 1895344 on the developing human fetus are unknown. For this reason and because DNA-damage response inhibitors agents as well as other therapeutic agents used in this trial, 5-FU and irinotecan, are known to be teratogenic, women of child-bearing potential and men must agree to use adequate contraception (hormonal or barrier method of birth control; abstinence) prior to study entry and for the duration of study participation and for 6 months after completion of BAY 1895344 administration
- Should a woman become pregnant or suspect she is pregnant while she or her partner is participating in this study, she should inform her treating physician immediately. Men treated or enrolled on this protocol must also agree to use adequate contraception prior to the study, for the duration of study participation, and 6 months after completion of study treatment administration
-
Ability to understand and the willingness to sign a written informed consent document. Participants with impaired decision-making capacity (IDMC) who have a legally-authorized representative (LAR) and/or family member available will also be eligible
Exclusion Criteria:
- Patients with a history of prior treatment with an ATR inhibitor
- Patients with a history of other malignancy that could affect compliance with the protocol or interpretation of the results
- Patients who have had chemotherapy or radiotherapy within 3 weeks (6 weeks for nitrosoureas or mitomycin C) prior to entering the study
- Patients who have not recovered from adverse events due to prior anti-cancer therapy (i.e., have residual toxicities > grade 1) with the exception of alopecia
- Patients who are receiving any other investigational agents
- History of hypersensitivity or allergic reactions attributed to compounds of similar chemical or biologic composition to BAY 1895344, 5-FU, leucovorin, or irinotecan. Patient eligibility can be discussed with the primary investigator (PI) if prior reactions do not seem to warrant excluding the patient
- Patients receiving any medications that are substrates of CYP3A4 with a narrow therapeutic window or strong inhibitors/inducers of CYP3A4 are ineligible, if they cannot be transferred to alternative medication. Because the lists of these agents are constantly changing, it is important to regularly consult a frequently-updated medical reference. As part of the enrollment/informed consent procedures, the patient will be counseled on the risk of interactions with other agents, and what to do if new medications need to be prescribed or if the patient is considering a new over-the-counter medicine or herbal product
- Patients with uncontrolled intercurrent illness
- Patients with psychiatric illness/social situations that would limit compliance with study requirements
- Gastrointestinal pathology or history that adversely impact the ability to take or absorb oral medication
- Pregnant women are excluded from this study because BAY 1895344 as a DNA-damage response inhibitor may have the potential for teratogenic or abortifacient effects. Because there is an unknown but potential risk for adverse events in nursing infants secondary to treatment of the mother with BAY 1895344 breastfeeding should be discontinued if the mother is treated with BAY 1895344 and for 4 months after end of treatment. These potential risks may also apply to other agents used in this study
- Patients who were unable to tolerate prior irinotecan treatment are excluded from this study
- Patients with a corrected QT (QTc) interval >= 470 msec are excluded from this study
Studijní plán
Jak je studie koncipována?
Detaily designu
- Primární účel: Léčba
- Přidělení: N/A
- Intervenční model: Přiřazení jedné skupiny
- Maskování: Žádné (otevřený štítek)
Počet zbraní
Zbraně a zásahy
Skupina účastníků / ArmSkupina účastníků / Arm |
Intervence / LéčbaIntervence / Léčba |
|---|---|
|
Experimentální: Treatment (elimusertib, FOLFIRI)
Patients receive elimusertib PO QD on days 2, 3, 16, and 17 and irinotecan hydrochloride IV over 90 minutes, fluorouracil IV over 46 hours, and leucovorin calcium IV on days 1 and 15. Cycles repeat every 28 day in the absence of disease progression or unacceptable toxicity. Patients undergo tumor biopsy during screening and on study and blood sample collection and imaging throughout the study. |
Given IV
Ostatní jména:
Undergo blood sample collection
Ostatní jména:
Undergo tumor biopsy
Ostatní jména:
Given IV
Ostatní jména:
Given IV
Ostatní jména:
Undergo imaging
Ostatní jména:
Given PO
Ostatní jména:
|
Co je měření studie?
Primární výstupní opatření
Primární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Maximum Tolerated Dose (MTD) of Elimusertib (BAY 1895344) in Combination With Irinotecan, Fluorouracil, and Leucovorin (FOLFIRI)
Časové okno: Up to 28 days
|
A BOIN - Bayesian Optimal intervals trial design will be used to determine the MTD. |
Up to 28 days
|
|
Patients Who Experienced DLTs
Časové okno: Up to 28 days
|
Percentage of Patients Who Experienced Dose Limiting Toxicities (DLTs) , per CTCAE v5.0 |
Up to 28 days
|
Sekundární výstupní opatření
Sekundární výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
12-month Progression-free Survival (PFS) - Total Population
Časové okno: At 12 months
|
Percentage of patients with Progression-free survival (PFS) will be estimated within disease cohorts by the product-limit (Kaplan-Meier) estimator, along with 95% confidence regions, from start of treatment to time of progression or death, whichever occurs first. Per RECIST v1.1 Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). |
At 12 months
|
|
24-month Progression-free Survival (PFS) - Total Population
Časové okno: At 24 months
|
Percentage of patients with Progression-free survival (PFS) will be estimated within disease cohorts by the product-limit (Kaplan-Meier) estimator, along with 95% confidence regions, from start of treatment to time of progression or death, whichever occurs first. Per RECIST v1.1 Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). |
At 24 months
|
|
Cmax of Irinotecan (Lead in)
Časové okno: Up to 1 year post treatment
|
Concentration Maximum (Cmax) of irinotecan and 5FU in Lead-in phase. |
Up to 1 year post treatment
|
|
AUC of Irinotecan (Lead in)
Časové okno: Up to 1 year post treatment
|
Area Under the Curve (AUC) of irinotecan and 5FU in Lead-in phase. |
Up to 1 year post treatment
|
|
AUC of 5FU (Lead-in)
Časové okno: Up to 1 year post treatment
|
Area Under the Curve (AUC) of irinotecan and 5FU in Lead-in phase. |
Up to 1 year post treatment
|
|
Cmax of Irinotecan (Combination)
Časové okno: Up to 1 year post treatment
|
Concentration Maximum (Cmax) of irinotecan in Combination (BAY + 5FU and Irinotecan) phase. |
Up to 1 year post treatment
|
|
AUC of Irinotecan (Combination)
Časové okno: Up to 1 year post treatment
|
Area Under the Curve (AUC) of irinotecan in Combination (BAY + 5FU and Irinotecan) phase. |
Up to 1 year post treatment
|
|
AUC of 5FU (Combination)
Časové okno: Up to 1 year post treatment
|
Area Under the Curve (AUC) of 5FU in Combination (BAY + 5FU and Irinotecan) phase |
Up to 1 year post treatment
|
|
Cmax of BAY 1895344
Časové okno: Up to 1 year post treatment
|
Concentration maximum (Cmax) of BAY 1895344. |
Up to 1 year post treatment
|
|
AUC-6 of BAY 1895344
Časové okno: Up to 1 year post treatment
|
Area Under the Curve of BAY 1895344. |
Up to 1 year post treatment
|
|
AUC of BAY 1895344
Časové okno: Up to 1 year post treatment
|
AUC of BAY 1895344 |
Up to 1 year post treatment
|
|
Overall Response Rate (ORR)
Časové okno: Up to 1 year post treatment
|
Percent probability of Complete Response (CR) or Partial Response (PR) per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes (target or non-target) with reduction in short axis to <10 mm; PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters. |
Up to 1 year post treatment
|
|
Clinical Benefit Rate (CBR)
Časové okno: Up to 1 year post treatment
|
Percent probability of Complete Response (CR), Partial Response (PR) or Stable Disease (SD) per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes (target or non-target) with reduction in short axis to <10 mm; PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters or SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters. |
Up to 1 year post treatment
|
|
Best Response
Časové okno: Up to 1 year post treatment
|
Number of patients with Complete Response (CR), Partial Response (PR), Stable Disease (SD) or Progressive Disease (PD) per RECIST v1.1, CR: Disappearance of all target lesions. Any pathological lymph nodes (target or non-target) with reduction in short axis to <10 mm; PR: ≥30% decrease in the sum of diameters of target lesions, taking as reference the baseline sum diameters or SD: Neither sufficient shrinkage to qualify for PR nor sufficient increase to qualify for PD, taking as reference the smallest sum diameters. PD: At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). |
Up to 1 year post treatment
|
|
Progression-free Survival (PFS) - by Dose Level
Časové okno: Up to 24 months post treatment
|
Median PFS will be estimated within disease cohorts by the product-limit (Kaplan-Meier) estimator, along with 95% confidence regions. Measured from start of treatment to time of progression or death, whichever occurs first. Per RECIST v1.1 Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). |
Up to 24 months post treatment
|
|
12-month Progression-free Survival (PFS) - by Dose Level
Časové okno: At 12 months
|
Proportion of patients with Progression-free survival (PFS) will be estimated within disease cohorts by the product-limit (Kaplan-Meier) estimator, along with 95% confidence regions, from start of treatment to time of progression or death, whichever occurs first. Per RECIST v1.1 Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). |
At 12 months
|
|
24-month Progression-free Survival (PFS) - by Dose Level
Časové okno: At 24 months
|
Proportion of patients with Progression-free survival (PFS) will be estimated within disease cohorts by the product-limit (Kaplan-Meier) estimator, along with 95% confidence regions, from start of treatment to time of progression or death, whichever occurs first. Per RECIST v1.1 Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). |
At 24 months
|
|
Progression-free Survival (PFS) - Total Population
Časové okno: Up to 24 months post treatment
|
Median PFS will be estimated within disease cohorts by the product-limit (Kaplan-Meier) estimator, along with 95% confidence regions. Measured from start of treatment to time of progression or death, whichever occurs first. Per RECIST v1.1 Progressive Disease (PD): At least a 20% increase in the sum of diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progression). |
Up to 24 months post treatment
|
|
Overall Survival (OS) - by Dose Level
Časové okno: Up to 24 months post treatment
|
Median number of months patients are alive from start of treatment until death while on study will be estimated within disease cohorts (KM estimator), with 95% CI. |
Up to 24 months post treatment
|
|
12- Month Overall Survival (OS) - By Dose Level
Časové okno: At 12 months
|
Proportion of patients alive estimated within disease cohorts by the product-limit (Kaplan-Meier) estimator, along with 95% confidence regions, from start of treatment to time of death. |
At 12 months
|
|
24-month Overall Survival (OS)
Časové okno: At 24 months
|
Proportion of patients alive estimated within disease cohorts by the product-limit (Kaplan-Meier) estimator, along with 95% confidence regions, from start of treatment to time of death while on study. |
At 24 months
|
|
Overall Survival (OS) - Total Population
Časové okno: Up to 2 years post treatment
|
Median number of months patients alive from start of treatment until death while on study will be estimated within disease cohorts by the product-limit (Kaplan-Meier) estimator, along with 95% confidence regions. |
Up to 2 years post treatment
|
|
12-month Overall Survival (OS) - Total Population
Časové okno: At 12 months
|
Proportion of patients alive estimated by the product-limit (Kaplan-Meier) estimator, along with 95% confidence regions, from start of treatment. |
At 12 months
|
|
24-month Overall Survival (OS) - Total Population
Časové okno: At 24 months
|
Proportion of patients alive estimated by the product-limit (Kaplan-Meier) estimator, along with 95% confidence regions, from start of treatment. |
At 24 months
|
|
ATM Status
Časové okno: Up to 1 year post treatment
|
Will be assessed by immunohistochemistry (IHC) and PFS. The association between ATM and responses will be described, with a table outlining patients who achieved progressive disease, stable disease, partial or complete responses and whether they exhibited ATM expression by IHC or not. |
Up to 1 year post treatment
|
|
Peripheral Blood Mononuclear Cell gammaH2AX and p-ATM Signaling
Časové okno: Up to 1 year post treatment
|
Signaling during the pharmacokinetics (PK) lead-in and in combination with BAY 1895344 will be compared with a non-parametric paired test (e.g. Wilcoxon rank test), at a significance level at p < 0.05. For tumors, this will be performed only for patients in the dose expansion cohorts. |
Up to 1 year post treatment
|
|
Tumor Multiplex Immunofluorescence Assay Signaling
Časové okno: Up to 1 year post treatment
|
Signaling during the PK lead-in and in combination with BAY 1895344 will be compared with a non-parametric paired test (e.g. Wilcoxon rank test), at a significance level at p < 0.05. For tumors, this will be performed only for patients in the dose expansion cohorts. |
Up to 1 year post treatment
|
Další výstupní opatření
Další výstupní opatření
Měření výsledku |
Popis opatření |
Časové okno |
|---|---|---|
|
Incidence of Adverse Events
Časové okno: Up to 1 year post treatment
|
Logistic regression and proportional hazards (Cox) regression will be used to assess the relationships between exposure and response and toxicity; exposure-response will be assessed within disease cohorts of sufficient size, while exposure-toxicity will pool all patients. All patients will be used for the E-R analyses. Advanced population PK methods may be employed at a later stage to assess the link between drug exposure and biological effects and efficacy. |
Up to 1 year post treatment
|
|
Status of Deoxyribonucleic Acid Damage Repair (DDR) Genes
Časové okno: Up to 1 year post treatment
|
Assessed by whole exome sequencing and ribonucleic acid sequencing. The efficacy analyses will be repeated by DDR tumor mutation status, but these analyses will have limited sample sizes and will not be adequately powered for statistical comparisons. |
Up to 1 year post treatment
|
Spolupracovníci a vyšetřovatelé
Sponzor
Sponzor
Vyšetřovatelé
Vyšetřovatelé
- Vrchní vyšetřovatel: Liza C Villaruz, University of Pittsburgh Cancer Institute LAO
Publikace a užitečné odkazy
Termíny studijních záznamů
Hlavní termíny studia
Začátek studia (Aktuální)
Začátek studia
Primární dokončení (Aktuální)
Primární dokončení
Dokončení studie (Odhadovaný)
Dokončení studie
Termíny zápisu do studia
První předloženo
První předloženo
První předloženo, které splnilo kritéria kontroly kvality
První předloženo, které splnilo kritéria kontroly kvality
První zveřejněno (Aktuální)
První zveřejněno
Aktualizace studijních záznamů
Poslední zveřejněná aktualizace (Aktuální)
Poslední zveřejněná aktualizace
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Odeslaná poslední aktualizace, která splnila kritéria kontroly kvality
Naposledy ověřeno
Naposledy ověřeno
Více informací
Termíny související s touto studií
Další relevantní podmínky MeSH
- Novotvary podle místa
- Novotvary
- Střevní nemoci
- Gastrointestinální novotvary
- Novotvary trávicího systému
- Nemoci trávicího systému
- Gastrointestinální onemocnění
- Onemocnění žaludku
- Střevní novotvary
- Rektální onemocnění
- Onemocnění tlustého střeva
- Novotvary žaludku
- Kolorektální novotvary
- Heterocyklické sloučeniny, 1 kruh
- Heterocyklické sloučeniny
- Heterocyklické sloučeniny, 2-prsten
- Heterocyklické sloučeniny, fúzované kroužek
- Vyšetřovací techniky
- Klinické laboratorní techniky
- Diagnostické techniky a postupy
- Diagnóza
- Chirurgické postupy, operativní
- Cytologické techniky
- Cytodiagnosis
- Fyzické jevy
- Camptothecin
- Alkaloidy
- Enzymy a koenzymy
- Pyrimidiny
- Diagnostické techniky, chirurgické
- Formyltetrahydrofoláty
- Tetrahydrofoláty
- Kyselina listová
- Pteriny
- Pteridiny
- Uracil
- Pyrimidinony
- Koenzymy
- Elektromagnetické jevy
- Magnetické jevy
- Elektromagnetické záření
- Záření
- Záření, ionizující
- Irinotekan
- Fluorouracil
- Leukovorin
- Biopsie
- Manipulace se vzorkem
- Rentgenové paprsky
- Dehydroftorafur
- Bay 1895344
Další identifikační čísla studie
Další identifikační čísla studie
- NCI-2020-06482
- UM1CA186690 (Grant/smlouva NIH USA)
- NCI-2020-06482 (Identifikátor registru: CTRP (Clinical Trial Reporting Program))
- 10406 (Jiný identifikátor: CTEP)
- 21-060
- 10406 (Jiný identifikátor: UPMC Hillman Cancer Center LAO)
Plán pro data jednotlivých účastníků (IPD)
Plánujete sdílet data jednotlivých účastníků (IPD)?
Popis plánu IPD
NCI is committed to sharing data in accordance with NIH policy. For more details on how clinical trial data is shared, access the link to the NIH data sharing policy page.
Informace o lécích a zařízeních, studijní dokumenty
Studuje lékový produkt regulovaný americkým FDA
Studuje produkt zařízení regulovaný americkým úřadem FDA
Tyto informace byly beze změn načteny přímo z webu clinicaltrials.gov. Máte-li jakékoli požadavky na změnu, odstranění nebo aktualizaci podrobností studie, kontaktujte prosím register@clinicaltrials.gov. Jakmile bude změna implementována na clinicaltrials.gov, bude automaticky aktualizována i na našem webu .